Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
As of close of business last night, Y-Mabs Therapeutics Inc’s stock clocked out at $5.80, down -2.85% from its previous closing price of $5.97. In other words, the price has decreased by -$2.85 from its previous closing price. On the day, 0.73 million shares were traded. YMAB stock price reached its highest trading level at $6.1 during the session, while it also had its lowest trading level at $5.7098.
Ratios:
To gain a deeper understanding of YMAB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.54 and its Current Ratio is at 3.92. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on November 18, 2024, initiated with a Outperform rating and assigned the stock a target price of $23.
On August 16, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $20.
On June 28, 2024, Truist started tracking the stock assigning a Buy rating and target price of $21.Truist initiated its Buy rating on June 28, 2024, with a $21 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 13 ’24 when Gad Thomas sold 65,000 shares for $13.47 per share. The transaction valued at 875,550 led to the insider holds 97,681 shares of the business.
Gad Thomas sold 30,000 shares of YMAB for $389,100 on Sep 16 ’24. The CHIEF BUSINESS OFFICER now owns 67,681 shares after completing the transaction at $12.97 per share. On Sep 13 ’24, another insider, Thomas Gad, who serves as the Officer of the company, bought 100,000 shares for $13.74 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, YMAB now has a Market Capitalization of 259776784 and an Enterprise Value of 192729648. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.07 while its Price-to-Book (P/B) ratio in mrq is 2.81. Its current Enterprise Value per Revenue stands at 2.279 whereas that against EBITDA is -8.253.
Stock Price History:
The Beta on a monthly basis for YMAB is 0.67, which has changed by -0.5607064 over the last 52 weeks, in comparison to a change of 0.21926713 over the same period for the S&P500. Over the past 52 weeks, YMAB has reached a high of $20.90, while it has fallen to a 52-week low of $5.93. The 50-Day Moving Average of the stock is -31.28%, while the 200-Day Moving Average is calculated to be -51.75%.
Shares Statistics:
It appears that YMAB traded 358.12K shares on average per day over the past three months and 441590 shares per day over the past ten days. A total of 44.77M shares are outstanding, with a floating share count of 36.97M. Insiders hold about 17.46% of the company’s shares, while institutions hold 60.22% stake in the company. Shares short for YMAB as of 1736899200 were 3739171 with a Short Ratio of 10.44, compared to 1734048000 on 3619213. Therefore, it implies a Short% of Shares Outstanding of 3739171 and a Short% of Float of 10.01.
